Last reviewed · How we verify
Psychopharmacotherapy
At a glance
| Generic name | Psychopharmacotherapy |
|---|---|
| Sponsor | Federal University of Rio Grande do Sul |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of a Pragmatic, Metabolic Care Clinic for Patients With Severe Mental Illness - The Meta Care Clinic (NA)
- Psychopharmacotherapy for Depressive Patients (NA)
- Elderly Demented Patients: Aromatherapy Complementary to Psychopharmacotherapy Psychological Disorders and BPSD Behavior (NA)
- Use of Intranasal Oxytocin During Detoxification of Crack Cocaine (PHASE1, PHASE2)
- Online Intervention for Depression: MOOD (NA)
- Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder (NA)
- Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression (NA)
- Psychopharmacotherapy in Multiple Substances Abuse (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Psychopharmacotherapy CI brief — competitive landscape report
- Psychopharmacotherapy updates RSS · CI watch RSS
- Federal University of Rio Grande do Sul portfolio CI